A Polymorphism in the VKORC1 Regulator Calumenin Predicts Higher Warfarin Dose Requirements in African Americans
- 3 March 2010
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 87 (4), 445-451
- https://doi.org/10.1038/clpt.2009.291
Abstract
Warfarin demonstrates a wide interindividual variability in response that is mediated partly by variants in cytochrome P450 2C9 (CYP2C9) and vitamin K 2,3‐epoxide reductase complex subunit 1 (VKORC1)...This publication has 40 references indexed in Scilit:
- The largest prospective warfarin-treated cohort supports genetic forecastingBlood, 2009
- Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfectionThrombosis Research, 2008
- VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African–Americans and European–AmericansPharmacogenomics, 2008
- Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patientsJournal of Thrombosis and Haemostasis, 2008
- Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? YesJournal of Thrombosis and Haemostasis, 2008
- A genome-wide scan for common genetic variants with a large influence on warfarin maintenance doseBlood, 2008
- Influence ofCYP2C9andVKORC1on warfarin dose, anticoagulation attainment and maintenance among European–Americans and African–AmericansPharmacogenomics, 2008
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology & Therapeutics, 2008
- WGAViewer: Software for genomic annotation of whole genome association studies: Figure 1.Genome Research, 2008
- Factors Influencing Warfarin Dose Requirements in African–AmericansPharmacogenomics, 2007